Form 4: Charles River Labs Exec Trades Shares

Joseph W. LaPlume, EVP of Corp Strategy & Develop at Charles River Laboratories, reported transactions involving common stock.

Summary

• Joseph W. LaPlume, Executive Vice President of Corporate Strategy & Development, reported the acquisition of 5,257 shares of common stock on May 29, 2026, at a price of $180.71 per share.
• Following this acquisition, LaPlume disposed of 744 shares on May 30, 2026, and an additional 235 shares on May 31, 2026, both at the same price of $180.71 per share.
• These transactions resulted in a net decrease in directly held common stock, with 31,298 shares beneficially owned after the reported transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and vesting schedules without indicating significant positive or negative strategic shifts.

Positives

• Acquisition of 5,257 shares of common stock at a reported price of $180.71 per share on May 29, 2026, indicates a potential investment or compensation-related event.
• The reporting person, Joseph W. LaPlume, holds a significant executive position (EVP, Corp Strategy & Develop), suggesting these transactions are part of a broader compensation or investment strategy.

Negatives

• Disposal of 744 shares on May 30, 2026, and 235 shares on May 31, 2026, at the same price of $180.71 per share, indicates a reduction in directly held beneficial ownership.

Future Outlook

Unvested restricted stock units are scheduled to vest annually on May 29th of 2027, 2028, 2029, and 2030.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive trading activities. These reports are crucial for investors monitoring potential shifts in insider confidence or compensation structures within the life sciences and contract research organization (CRO) sector.

Stakeholder Impact

• Shareholders: The transactions provide insight into executive stock holdings and potential future share availability through vesting schedules.
• Employees: The vesting schedule for restricted stock units indicates ongoing incentive programs for key personnel.
• Management: The transactions reflect the executive's personal investment and compensation strategy related to company stock.

Next Steps

• Continued vesting of restricted stock units through May 29, 2030.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Charles River Laboratories, Joseph W. LaPlume, Common Stock, Beneficial Ownership, Executive Transactions